Alle verbonden artikelen

Response to letter entitled: Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.

Auteurs : Agostinetto E, Ceppi M, Bruzzone M, Lambertini M, de Azambuja E
Jaar : 2021
Journal : Eur J Cancer
Volume : 155
Pagina's : 303-306

Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.

Auteurs : Guerini-Rocco E, Gray KP, Fumagalli C, Reforgiato MR, Leone I, Rafaniello Raviele P, Munzone E, Kammler R, Neven P, Hitre E, Jerusalem G, Simoncini E, Gombos A, Deleu I, Karlsson P, Aebi S, Chirgwin J, Di Lauro V, Thompson A, Graas MP, Barber M, Fontaine C, Loibl S, Gavilá J, Kuroi K, Müller B, OReilly S, Di Leo A, Goldhirsch A, Viale G, Barberis M, Regan MM, Colleoni M
Jaar : 2021
Journal : Clin Cancer Res
Volume : 27
Pagina's : 504-512

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.

Auteurs : Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart-Gebhart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI
Jaar : 2021
Journal : ESMO Open
Volume : 6
Pagina's : 100117

Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research.

Auteurs : Cogels MM, Rouas R, Ghanem GE, Martinive P, Awada A, Van Gestel D, Krayem M
Jaar : 2021
Journal : Front Oncol
Volume : 11
Pagina's : 784947

Impact of HIV infection on baseline characteristics and survival of women with breast cancer.

Auteurs : Brandão M, Bruzzone M, Franzoi MA, de Angelis C, Eiger D, Caparica R, Piccart-Gebhart M, Buisseret L, Ceppi M, Dauby N, Carrilho C, Lunet N, de Azambuja E, Lambertini M
Jaar : 2021
Journal : AIDS
Volume : 35
Pagina's : 605-618

Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics.

Auteurs : Saini KS, Punie K, Twelves C, Bortini S, de Azambuja E, Anderson S, Criscitiello C, Awada A, Loi S
Jaar : 2021
Journal : Expert Opin Biol Ther
Volume : 21
Pagina's : 945-962

Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.

Auteurs : Jerusalem G, Farah S, Courtois A, Chirgwin J, Aebi S, Karlsson P, Neven P, Hitre E, Graas MP, Simoncini E, Abdi E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, OReilly S, Gombos A, Ruhstaller T, Burstein HJ, Rabaglio M, Ruepp B, Ribi K, Viale G, Gelber Rd, Coates AS, Loi S, Goldhirsch A, Regan MM, Colleoni M
Jaar : 2021
Journal : Ann Oncol
Volume : 32
Pagina's : 1256-1266

Anal squamous cell carcinoma: standards of care, new data and ongoing clinical trials.

Auteurs : Giunta EF, Bregni G, Hendlisz A, Sclafani F
Jaar : 2021
Journal : Curr Opin Oncol
Volume : 33
Pagina's : 372-377

Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma.

Auteurs : Bouchart C, Engelholm JL, Closset J, Navez J, Loi P, Gökburun Y, De Grez T, Mans L, Hendlisz A, Bali MA, Eisendrath P, Van Gestel D, Hein M, Moretti L, Van Laethem JL
Jaar : 2021
Journal : Ther Adv Med Oncol
Volume : 13
Pagina's : 17588359211045860

Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.

Auteurs : Deleporte A, Van den Eynde M, Forget F, Holbrechts S, Delaunoit T, Houbiers G, Kalantari HR, Laurent S, Vanderstraeten E, De Man M, Vergauwe P, Clausse M, Van Der Auwera J, DHondt L, Pierre P, Ghillemijn B, Covas A, Paesmans M, Ameye L, Awada A, Sclafani F, Hendlisz A
Jaar : 2021
Journal : Cancer Med
Volume : 10
Pagina's : 4366-4374

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.

Auteurs : De Caluwe A, Buisseret L, Poortmans P, Van Gestel D, Salgado R, Sotiriou C, Larsimont D, Paesmans M, Craciun L, Drisis S, Vandekerckhove C, Reyal F, Veys I, Eiger D, Piccart-Gebhart M, Romano E, Ignatiadis M
Jaar : 2021
Journal : BMC Cancer
Volume : 21
Pagina's : 899

Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study.

Auteurs : Goudsmit A, Cubilier E, Meert AP, Aftimos P, Stathopoulos K, Spilleboudt C, Loizidou A
Jaar : 2021
Journal : Support Care Cancer

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.

Auteurs : Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Lorca FP, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N
Jaar : 2021
Journal : Ann Oncol

Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis.

Auteurs : Tagliamento M, Agostinetto E, Bruzzone M, Ceppi M, Saini KS, de Azambuja E, Punie K, Westphalen CB, Morgan G, Pronzato P, Del Mastro L, Poggio F, Lambertini M
Jaar : 2021
Journal : Crit Rev Oncol Hematol
Pagina's : 103365

Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.

Auteurs : Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HC, Saunders C, Cardoso F, Susnjar S, Bjelic-Radisic V, Smith KL, Piccart-Gebhart M, Korde LA, Goldhirsch A, Gelber Rd, Pagani O
Jaar : 2021
Journal : Breast
Volume : 59
Pagina's : 327-338

Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

Auteurs : El Hachem G, Gombos A, Awada A
Jaar : 2021
Journal : Expert Rev Anticancer Ther
Volume : 21
Pagina's : 81-92

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.

Auteurs : Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, OShaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS
Jaar : 2021
Journal : N Engl J Med
Volume : 384
Pagina's : 1529-1541

Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae.

Auteurs : Plaçais L, Michot JM, Champiat S, Romano-Martin P, Baldini C, Joao MS, Marabelle A, Voisin AL, Not A, Labeyrie C, Beaudonnet G, Laparra A, Maria ATJ, Masseau A, Dehette S, Deleporte A, Echaniz-Laguna A, Denier C, Adams D, Lambotte O, Noel N, Cauquil C
Jaar : 2021
Journal : Brain Commun
Volume : 3
Pagina's : fcab220

Precision medicine in breast cancer: From clinical trials to clinical practice.

Auteurs : Crimini E, Repetto M, Aftimos P, Botticelli A, Marchetti P, Curigliano G
Jaar : 2021
Journal : Cancer Treat Rev
Volume : 98
Pagina's : 102223

Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis.

Auteurs : Caparica R, Bruzzone M, Agostinetto E, Franzoi MA, Ceppi M, Radosevic-Robin N, Penault-Llorca F, Willard-Gallo K, Loi S, Salgado R, de Azambuja E
Jaar : 2021
Journal : Breast
Volume : 59
Pagina's : 183-192